Forest To Review Role In Desmoteplase Program Following DIAS-2 Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Development of Forest/Paion's clot dissolving protein desmoteplase for the treatment of acute ischemic stroke could be in question after a Phase III study failed to show an efficacy benefit in patients treated with the drug versus placebo